Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial

https://doi.org/10.1016/S0037-1963(01)90096-4Get rights and content

Abstract

Venous thromboembolism (VTE) is a common complication of hospitalized patients, imposing a major clinical and economic burden. Three of four cases of fatal pulmonary embolism occur in nonsurgical settings, but thromboprophylaxis is far less common in medical than in surgical patients. This is mainly attributable to the heterogeneity of nonsurgical populations and lack of high-quality evidence to support specific thromboprophylactic measures. The recent Prophylaxis of Venous Thromboembolism in MEDical Patients With ENOXaparin (MEDENOX) trial addressed this deficiency by assessing the need for and the benefit:risk ratio of thromboprophylaxis in a well-defined group of medical patients immobilized with severe illness. The MEDENOX study showed that these patients are at significant risk of VTE. Enoxaparin, 40 mg once daily for 6 to 14 days, reduced the risk of VTE by 63% without increasing adverse events. It is anticipated that data from the MEDENOX study will be incorporated into future consensus guidelines on the prevention of VTE. Further studies are required to assess the benefit:risk ratio of therapy in other clearly-defined medical groups.

References (36)

  • International Consensus Statement: Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)

    Int Angiol

    (1997)
  • O Hauch et al.

    Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery

  • Risk of and prophylaxis for venous thromboembolism in hospital patients

    Phlebology

    (1998)
  • DA Sandler et al.

    Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis?

    J R Soc Med

    (1989)
  • AT Cohen et al.

    The changing pattern of venous thromboembolic disease

    Haemostasis

    (1996)
  • FA Anderson et al.

    Physician practices in the prevention of venous thromboembolism

    Ann Intern Med

    (1991)
  • Risk of and prophylaxis for venous thromboembolism in hospital patients

    BMJ

    (1992)
  • JJ Belch et al.

    Prevention of deep vein thrombosis in medical patients by lowdose heparin

    Scott Med J

    (1981)
  • Cited by (21)

    • Thromboembolism in lung cancer - An area of urgent unmet need

      2014, Lung Cancer
      Citation Excerpt :

      It is a potent negative predictor of survival and a leading cause of death [1,6]. Appropriate pharmacological thromboprophylaxis (P-TP) can be a highly cost-effective preventative strategy with the potential to reduce the incidence of TE in high-risk patients by up to 80% [7–9]. While all patients with cancer should be considered at risk of TE, the risk is dynamic, and the absolute magnitude and duration of TE risk is not equal for all patients or for a given individual over time.

    • Haemostatic challenges in the cancer patient: Focus on the perioperative period

      2013, Best Practice and Research: Clinical Anaesthesiology
      Citation Excerpt :

      Registry and retrospective studies have demonstrated that postoperative TE results in excess length of hospital stay, excess mortality and health costs [36]. Importantly, TE is preventable with appropriate utilisation of P-TP in up to 80% of high-risk patients, with substantial clinical evidence from randomised controlled trials (RCTs) and meta-analyses supporting its safety and cost-effectiveness [37–42]. Economic evaluation of hospitalised and surgical cancer patients has shown cost benefit with the administration of P-TP, largely due to the increased morbidity (and mortality) and requirement for increase health resource utilisation associated with TE.

    • Venous thromboembolism in acutely ill hospitalized medical patients

      2010, Thrombosis Research
      Citation Excerpt :

      The implementation of thromboprophylaxis strategies provides benefit to patients, and should also help protect their caregivers and hospitals for legal liability [2]. Unfortunately, despite the number of randomized trials demonstrating the benefit of thromboprophylaxis [3–6], low adherence is frequent, and the number of patient with VTE is higher than expected, [7–9] specially in medical populations [3]. A number of reasons may account for this situation: the apparent greater heterogeneity of medical patients compared with surgical patient may limit accurate assessment of the overall burden of VTE in medical patients; identifying individual medical patient at high risk for VTE may seem difficult.

    • Treatment and prevention of thrombosis during treatment of lung cancer

      2009, Revue des Maladies Respiratoires Actualites
    • Venous thromboembolism and cancer

      2008, Revue de Pneumologie Clinique
    View all citing articles on Scopus

    Based on a presentation delivered at a satellite symposium to the 1999 meeting of the International Society on Thrombosis and Haemostasis.

    View full text